NASDAQ:ICCM

IceCure Medical (ICCM) Stock Forecast, Price & News

$0.61

-0.05 (-7.57%)

(As of 09/22/2023 ET)

Compare

Today's Range: $0.61
▼
$0.67
50-Day Range: $0.58
▼
$1.23
52-Week Range: $0.52
▼
$4.73

Volume: 351,283 shs
Average Volume: 218,001 shs
Market Capitalization: $27.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.33

IceCure Medical MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 446.2% Upside
$3.33 Price Target
Short Interest: Healthy
0.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.30
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.36) to ($0.39) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

842nd out of 963 stocks

Surgical & Medical Instruments Industry

86th out of 97 stocks

3.5

Analyst's Opinion

Consensus Rating
IceCure Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.33, IceCure Medical has a forecasted upside of 446.2% from its current price of $0.61.
Amount of Analyst Coverage
IceCure Medical has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.40% of the float of IceCure Medical has been sold short.
Short Interest Ratio / Days to Cover
IceCure Medical has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in IceCure Medical has recently increased by 128.00%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
IceCure Medical does not currently pay a dividend.
Dividend Growth
IceCure Medical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ICCM.

1.5

News and Social Media Coverage

News Sentiment
IceCure Medical has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for IceCure Medical this week, compared to 1 article on an average week.
MarketBeat Follows
3 people have added IceCure Medical to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IceCure Medical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.44% of the stock of IceCure Medical is held by insiders.
Percentage Held by Institutions
Only 0.34% of the stock of IceCure Medical is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for IceCure Medical are expected to decrease in the coming year, from ($0.36) to ($0.39) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IceCure Medical is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IceCure Medical is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IceCure Medical has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IceCure Medical (NASDAQ:ICCM) Stock

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

ICCM Price History

30 days | 90 days | 365 days | Advanced Chart

ICCM Stock News Headlines

September 22, 2023 | finance.yahoo.com

Renowned Spanish Radiologist Lucía Graña-López to Present Data Using IceCure Medical's ProSense at European Society of Breast Imaging Scientific Meeting 2023

September 21, 2023 | msn.com

Why Is Medical Device Firm IceCure Medical Stock Trading Lower Today?

September 24, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

September 20, 2023 | msn.com

IceCure Medical shares plunge 40% on FDA update

September 20, 2023 | markets.businessinsider.com

Icecure Medical (ICCM) Receives a Buy from H.C. Wainwright

September 8, 2023 | finance.yahoo.com

IceCure Medical to Join Hands-On Cryoablation Session with ProSense and Host Symposium Led by Renowned Doctors at the CIRCE 2023 Annual Congress

September 6, 2023 | markets.businessinsider.com

Expert Ratings for Icecure Medical

September 6, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Icecure Medical (ICCM)

September 24, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

August 31, 2023 | msn.com

Icecure Medical (ICCM) Price Target Increased by 37005.92% to 4.01

August 28, 2023 | finance.yahoo.com

IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America

August 21, 2023 | finance.yahoo.com

IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium

August 16, 2023 | markets.businessinsider.com

Icecure Medical (ICCM) Receives a Buy from Maxim Group

August 16, 2023 | finance.yahoo.com

IceCure Medical Second Quarter 2023 Earnings: EPS Misses Expectations

August 15, 2023 | msn.com

Alliance Global Partners Maintains Icecure Medical (ICCM) Buy Recommendation

August 15, 2023 | msn.com

HC Wainwright & Co. Reiterates Icecure Medical (ICCM) Buy Recommendation

August 15, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Icecure Medical (ICCM)

August 15, 2023 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Icecure Medical

August 14, 2023 | finance.yahoo.com

IceCure Medical Reports First Half 2023 Financial & Operational Results: Global Adoption of Cryoablation Technology Gaining Momentum

August 7, 2023 | finance.yahoo.com

IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023

August 1, 2023 | fool.com

IceCure Medical (NASDAQ: ICCM)

July 27, 2023 | finance.yahoo.com

IceCure Medical's (NASDAQ:ICCM) investors will be pleased with their enviable 577% return over the last three years

July 25, 2023 | markets.businessinsider.com

Maxim Group Sticks to Their Buy Rating for Icecure Medical (ICCM)

July 25, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Icecure Medical (ICCM)

July 24, 2023 | finance.yahoo.com

Health Canada Approves IceCure Medical's Minimally Invasive ProSense Cryoablation System

July 17, 2023 | finance.yahoo.com

IceCure Medical Expands Distribution of ProSense® into Portugal Through Agreement with Medicinália Cormédica: Upfront Systems & Probes Sales

June 13, 2023 | finance.yahoo.com

IceCure Medical to Review Recent Progress at Maxim Group's Virtual Healthcare Conference

See More Headlines

Receive ICCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IceCure Medical and its competitors with MarketBeat's FREE daily newsletter.

ICCM Company Calendar

Last Earnings: 8/14/2023
Today: 9/24/2023
Next Earnings (Estimated): 12/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ICCM
CUSIP: N/A
CIK: 1584371
Web: www.icecure-medical.com
Phone: 972-4623-0333
Fax: 972-4623-0222
Employees: 65
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.33
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +446.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-16,980,000.00
Net Margins: -486.55%
Pretax Margin: -550.34%
Return on Equity: -77.22%
Return on Assets: -62.76%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 5.30
Quick Ratio: 4.59

Sales & Book Value

Annual Sales: $3.09 million
Price / Sales: 9.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.56 per share
Price / Book: 1.09

Miscellaneous

Outstanding Shares: 45,620,000
Free Float: 44,510,000
Market Cap: $27.84 million
Optionable: Not Optionable
Beta: 0.11

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Eyal Shamir (Age 62)
CEO & Director
Comp: $467.32k

Mr. Ronen Tsimerman CPA (Age 54)
CFO & COO
Comp: $331.8k

Ms. Tlalit Bussi Tel-Tzure (Age 52)
VP of Bus. Devel. & Global Marketing
Comp: $279.34k

Ms. Merav Nir Dotan (Age 54)
VP of HR
Comp: $197.96k

Ms. Galit Malik (Age 50)
VP of Operations & Service

Key Competitors

View All Competitors

ICCM Stock - Frequently Asked Questions

Should I buy or sell IceCure Medical stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IceCure Medical in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICCM shares.
View ICCM analyst ratings or view top-rated stocks.
What is IceCure Medical's stock price forecast for 2023?: 3 Wall Street research analysts have issued twelve-month target prices for IceCure Medical's stock. Their ICCM share price forecasts range from $3.00 to $4.00. On average, they expect the company's stock price to reach $3.33 in the next twelve months. This suggests a possible upside of 446.2% from the stock's current price.
View analysts price targets for ICCM or view top-rated stocks among Wall Street analysts.
How have ICCM shares performed in 2023?: IceCure Medical's stock was trading at $1.55 at the start of the year. Since then, ICCM stock has decreased by 60.6% and is now trading at $0.6103.
View the best growth stocks for 2023 here.
Are investors shorting IceCure Medical?: IceCure Medical saw a increase in short interest in August. As of August 31st, there was short interest totaling 79,800 shares, an increase of 128.0% from the August 15th total of 35,000 shares. Based on an average daily trading volume, of 139,700 shares, the short-interest ratio is presently 0.6 days. Currently, 0.4% of the company's shares are sold short.
View IceCure Medical's Short Interest.
When is IceCure Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, December 4th 2023.
View our ICCM earnings forecast.

How were IceCure Medical's earnings last quarter?: IceCure Medical Ltd (NASDAQ:ICCM) posted its quarterly earnings data on Monday, August, 14th. The company reported ($0.09) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.09). The business had revenue of $0.94 million for the quarter, compared to analysts' expectations of $0.80 million. IceCure Medical had a negative trailing twelve-month return on equity of 77.22% and a negative net margin of 486.55%.
What is IceCure Medical's stock symbol?: IceCure Medical trades on the NASDAQ under the ticker symbol "ICCM."
How do I buy shares of IceCure Medical?: Shares of ICCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IceCure Medical's stock price today?: One share of ICCM stock can currently be purchased for approximately $0.61.
How much money does IceCure Medical make?: IceCure Medical (NASDAQ:ICCM) has a market capitalization of $27.84 million and generates $3.09 million in revenue each year. The company earns $-16,980,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.
How can I contact IceCure Medical?: The official website for the company is www.icecure-medical.com. The company can be reached via phone at 972-4623-0333, via email at jeremy@lifesciadvisors.com, or via fax at 972-4623-0222.

This page (NASDAQ:ICCM) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial